(Updates)
** U.S.-listed shares of Chinese biopharma co Zai Lab Ltd
ZLAB.O up 10% to $35.31
** Co to present new data from early stage study of antibody
drug candidate to treat solid tumors at 2023 American Society of
Clinical Oncology Annual Meeting
** Says early data supports a solid tolerability profile and
preliminary antitumor activity
** There were no dose limiting toxicities as of the data
cut-off date in an evaluation of 10 patients
** Six patients achieved stable disease, in which cancer
neither increases or decreases in seveity or extent, and 3
patients show evidence of tumor regression
** Stock up 18% YTD
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))